Is Retatrutide the Same as “GLP-3”? What the Term Actually Means

If you’ve seen research peptide vendors refer to “GLP-3” or “GLP-3RT,” you may be wondering whether that’s a different compound from Retatrutide — it isn’t. Here’s the clarification.

“GLP-3” is not an official receptor classification

Retatrutide is a triple receptor agonist, acting on the GLP-1, GIP, and glucagon (GCGR) receptor pathways. “GLP-3” is informal shorthand some vendors and researchers use to describe this triple-agonist mechanism — it is not a distinct fourth incretin hormone or an official pharmacological classification. When you see “GLP-3,” “GLP-3RT,” or “Reta GLP-3” used to describe a product, it is referring to Retatrutide.

Why the terminology exists

Retatrutide’s triple-receptor mechanism is a step beyond dual GLP-1/GIP agonists like tirzepatide, and “GLP-3” shorthand emerged informally in research and online communities to describe that added receptor activity in a memorable way.

What matters more than the name

Regardless of naming convention, purity verification matters more for research validity than which shorthand a vendor uses. Every batch should have an independent Certificate of Analysis confirming identity and purity.

Peptryn’s Retatrutide

Peptryn’s Retatrutide is HPLC-verified to 99%+ purity by an independent US lab, with a published COA for every batch in our COA Library.

For laboratory research use only. Not for human consumption, self-administration, or veterinary use.